#read

Biotech in Germany gains in ideas but loses in money and jobs

The German biotech sector shows two faces. On the one hand, innovation and start-up spirit are bubbling up like never before. On the other hand, turnover and employment are slumping noticeably. In 2024, total turnover fell by eight per cent to eleven billion euros and the number of employees also shrank. At the same time, investment in biotech start-ups shot up to record levels. At 1.9 billion euros, almost twice as much capital flowed into young companies as in the previous year.

30/05/2025

However, the euphoria did not last long. The financing volume fell dramatically in the first quarter of 2025. The boom seems to be over for the time being. Nevertheless, there are rays of hope. The number of projects in phase 2 and phase 3 clinical trials is increasing, seed financing has tripled and the first IPO in years has brought a breath of fresh air to the stock market. Even if the international environment remains challenging and the road to M&A exits is bumpy, the pipeline and the inflow of capital clearly show one thing. The industry has enough ideas, now it needs a tailwind from politics and the capital market.

News from "BIO Deutschland", 20 May 2025

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content